Zobrazeno 1 - 10
of 144
pro vyhledávání: '"J. Kusel"'
Publikováno v:
California Agriculture, Vol 69, Iss 1 (2015)
In California and across the United States, landscape restoration projects often require cross-boundary cooperation, though successful examples are rare and not well understood. This case study describes the Burney Gardens timber harvesting plan, a c
Externí odkaz:
https://doaj.org/article/091ae7847a2c4b40bb326b80f256f51d
Autor:
J. Kusel, John Spoors
Publikováno v:
British Journal of Healthcare Management. 22:267-277
The era of high-priced specialty pharmaceuticals is moving towards a pivotal moment. The cascade effect from the number of high-priced pharmaceuticals coming to market both now and in the future is causing payers to experience affordability challenge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8179d2f75113f2cbd41ad5e1aec59bf0
https://doi.org/10.12968/bjhc.2016.22.5.267
https://doi.org/10.12968/bjhc.2016.22.5.267
Autor:
John Spoors, J. Kusel
Publikováno v:
British Journal of Healthcare Management. 21:331-342
With global healthcare budgets increasingly under pressure due to escalating costs, the spend on pharmaceuticals is a prime target for healthcare planners as it is the second largest budget item after staffing expenditure. Against this financial pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a57a8b8614f051d300962c6296b2eab
https://doi.org/10.12968/bjhc.2015.21.7.331
https://doi.org/10.12968/bjhc.2015.21.7.331
Publikováno v:
Journal of medical economics. 20(9)
Objective: Patients with relapsing-remitting multiple sclerosis (RRMS) treated with disease modifying therapies (DMTs) who continue to experience disease activity may be considered for escalation therapies such as fingolimod, or may be considered for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::832e15b43da573b5e1981227569ee007
https://pubmed.ncbi.nlm.nih.gov/28635362
https://pubmed.ncbi.nlm.nih.gov/28635362
Publikováno v:
Journal of medical economics. 20(5)
Objective: Two disease-modifying therapies are licensed in the EU for use in rapidly-evolving severe (RES) relapsing-remitting multiple sclerosis (RRMS), fingolimod and natalizumab. Here a discrete event simulation (DES) model to analyze the cost-eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b566f27fc42249a7700b57a6b11d386
https://pubmed.ncbi.nlm.nih.gov/28008769
https://pubmed.ncbi.nlm.nih.gov/28008769
Publikováno v:
Value in Health. 22:S802
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d113dabd05bb67af7886e6635046db31
https://doi.org/10.1016/j.jval.2019.09.2141
https://doi.org/10.1016/j.jval.2019.09.2141
Publikováno v:
Value in Health. 22:S263
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d8e1e8e81b816f882fe148723a069f5
https://doi.org/10.1016/j.jval.2019.04.1239
https://doi.org/10.1016/j.jval.2019.04.1239
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 17(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0eedb7210fa132b4d53705df5bd7033
https://pubmed.ncbi.nlm.nih.gov/27200949
https://pubmed.ncbi.nlm.nih.gov/27200949
Publikováno v:
Applied health economics and health policy. 14(5)
Budget impact analysis (BIA) has become an essential part of economic evaluation within health technology assessment. Several disease-modifying therapies (DMTs) are now available for the treatment of multiple sclerosis (MS). This study sought to iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cf88a2da03269bc1a9f6e08603bf228
https://pubmed.ncbi.nlm.nih.gov/27130689
https://pubmed.ncbi.nlm.nih.gov/27130689
Autor:
J. Kusel, Stephen Montgomery
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 16(3)
Children are not mini-adults, and thus require studies to be conducted in the population of interest to inform decisions about their care. The paucity of such studies for clinical efficacy lead them to be termed 'therapeutic orphans'. Following the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071a142b49ddb74329f7e5690a66b4af
https://pubmed.ncbi.nlm.nih.gov/27082293
https://pubmed.ncbi.nlm.nih.gov/27082293